Chinese Traditional and Herbal Drugs
|
2025, 56(16): 5749-5762
Schisandrin B-loaded by zein/dextran nanoparticles: Prescription optimization, characterization and oral pharmacokinetics
Full
WANG Xiaoyun1,2, LI Zeyun1,3, WANG Yun4, LAI Yaowen4
Affiliations
1 Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450002, China; 2 Henan Engineering Research Center of Clinical Mass Spectrometry for Precision Medicine, Zhengzhou 450052, China; 3 Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou 450052, China; 4 The Fifth Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou 450046, China
About Author:
河南省重点研发推广项目 (222102310082); 河南省科技研发计划联合基金项目 (301420098)
doi: 10.7501/j.issn.0253-2670.2025.16.005
Outline
Objective To prepare schisandrin B-loaded by zein-dextran nanoparticles (Sch B-zein/Dex-NPs), and examine its in vitro drug release behavior and in vivo pharmacokinetic behavior. Methods Anti-solvent precipitation method was used to prepare Sch B-zein/Dex-NPs. Influencing factors were investigated by single factor experiments, Box-Behnken design-response surface method (BBD-RSM) was employed to optimize prescriptions of Sch B-zein/Dex-NPs. Transmission electron microscope (TEM) was employed to observe the microscopic appearance of Sch B-zein/Dex-NPs, Fourier transform infrared spectrometer (FTIR) was used to study binding mechanism, X-ray powder diffraction (XRPD) was employed to analyze the crystal form of schisandrin B in Sch B-zein/Dex-NPs powder. Saturated solubility of Sch B-zein/Dex-NP powder was determined in distilled water, simulated gastric fluids and simulated intestinal fluids, and the in vitro drug release in simulated gastrointestinal fluids was investigated by dialysis bag method. SD rats were administered intragastrically with schisandrin B and Sch B-zein/Dex-NPs respectively, and main pharmacokinetic parameters were calculated. Results Optimal formulations of Sch B-zein/Dex-NPs: mass concentration of zein was 19.5 g/L, volume ratio of anti-solvent phase to solvent phase was 2.95:1 and mass concentration of dextran was 5.0 g/L. The envelopment efficiency, drug loading, particle size and ζ potential were (89.34 ±0.71)%, (4.91 ±0.05)%, (179.79 ±5.52) nm and (−32.16 ±0.69) mV, respectively. Appearance of Sch B-zein/Dex-NPs were spheroidal. Schisandrin B might complex with zein by hydrogen bond. The state of schisandrin B changed into an amorphous form in Sch B-zein/Dex-NPs powder. Sch B-zein/Dex-NPs increased the solubility of schisandrin B in distilled water, simulated gastric fluids and simulated intestinal fluids by 61.99, 65.13, and 64.38 times, respectively. Cumulative drug release of Sch B-zein/Dex-NPs in simulated gastric and intestinal fluids increased to 71.68% and 87.87% in 12 h, and the drug release behavior was both in accordance with Weibull model. Pharmacokinetic results showed that the tmax of Sch B-zein/Dex-NPs was postponed to (2.08 ±0.46) h, t1/2 was prolonged to (4.42 ±1.78) h. Cmax and relative oral bioavailability were increased to 3.82 and 4.36 times, respectively. Conclusion Encapsulation efficiency of Sch B-zein/Dex-NPs was more than 80%, and significantly increased the solubility, release rate and bioavailability of schisandrin B, which laid an experimental foundation for subsequent research.
schisandrin B
/
zein
/
dextran
/
Box-Behnken response surface design method
/
nanoparticles
/
solubility
/
release rate
/
bioavailability
王肖雲, 李泽运, 王贇, 赖耀文.
负载五味子乙素的玉米醇溶蛋白/葡聚糖纳米粒处方优化、表征及口服药动学研究.
中草药,
2025
, 56
(16)
: 5749
-5762
.
DOI: 10.7501/j.issn.0253-2670.2025.16.005
WANG Xiaoyun, LI Zeyun, WANG Yun, LAI Yaowen.
Schisandrin B-loaded by zein/dextran nanoparticles: Prescription optimization, characterization and oral pharmacokinetics[J].
Chinese Traditional and Herbal Drugs,
2025
, 56
(16)
: 5749
-5762
.
DOI: 10.7501/j.issn.0253-2670.2025.16.005
Year 2025 volume 56 Issue 16
41
0
Cite this Article
BibTeX
Article Info
doi: 10.7501/j.issn.0253-2670.2025.16.005
- Receive Date:2025-03-19
- Online Date:2026-11-12